{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-126973","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.476944+00:00","generated_at":"2026-06-21T05:01:25.659102+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Applied DNA Sciences FY2022 revenue up 101% to $18.2M; operating loss widens to $14.0M","bullets":["Total revenue $18.2M, +101% YoY; COVID-19 testing revenue $15.5M (85% of total).","Q4 revenue $3.6M (+17% Q/Q, +20% YoY); gross profit margin fell to 12% from 33%.","Operating loss $14.0M vs $13.3M; adjusted EBITDA -$9.9M.","Cash and equivalents $15.2M; secured $12M public offering and $3.7M warrant exercise in Q4.","Company plans cGMP capacity for linearDNA platform by end of CY2023; focuses on PGx testing and UFLP Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-126973","json":"https://secwatch.observer/filing/0001104659-22-126973.json","markdown":"https://secwatch.observer/filing/0001104659-22-126973.md","text":"https://secwatch.observer/filing/0001104659-22-126973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/0001104659-22-126973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/tm2232660d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:01:25.659102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a00bbddde6c0e0f9faf03beb445bfe73a522c9b","claim":"BNB PLUS CORP. reported the fiscal year ended September 30, 2022 results: revenue $18.2 million.","evidence_excerpt":"Total revenues increased 101% to $18.2 million, which included $15.5 million in clinical laboratory service revenues (COVID-19 test revenue).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/0001104659-22-126973-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended September 30, 2022"},{"label":"Revenue","value":"$18.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"72719309a51acfd1c882b892dda472775fc68d2f","claim":"BNB PLUS CORP. reported the fourth quarter ended September 30, 2022 results: revenue $3.6 million.","evidence_excerpt":"Total revenues increased 17% to $3.6 million, which included $2.9 million in clinical laboratory service revenues (COVID-19 testing revenue).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465922126973/0001104659-22-126973-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended September 30, 2022"},{"label":"Revenue","value":"$3.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}